Evaluation of Childhood Immune Thrombocytopenic Purpura Cases: 184 Case Experience of a Single Center

Year 2019, Volume: 7 Issue: Ek - IRUPEC 2019 Kongresi Tam Metin Bildirileri, 362 - 366, 10.12.2019

Mine Kıraç Hüseyin Tokgöz

Abstract

Purpose:
Immune thrombocytopenic purpura is the most frequently seen acquired bleeding disorder of childhood. It generally progresses with good prognosis and high spontaneous remission rate. Our study aims to evaluate the general characteristics of the patients followed at our clinic.
Material and Method:
Patients, who were diagnosed between 2000 and 2008 and whose follow-up periods exceeded six months at NEU Meram Medical Faculty Pediatric Hematology Department, were evaluated in this study.
Findings:
A total of 184 cases were taken under evaluation in this study. The male and female ratio was 1 (M/F: 1), and the age group in this patients were most frequently seen 1 to 10. The history of infection in acute ITP group was 49% and chronic ITP group was 17.9%. The most frequently observed history was the upper respiratory tract infection (67%). No difference was discovered among groups in terms of the distribution of symptoms. Application age and number of thrombocytes was significantly low in the acute group. The number of thrombocytes at the time of application of 63% of the patients with acute ITP was <10.000/mm3. The number of serologically proven infections was 30 (16.3%), with the most frequently encountered being EBV positive. The rate of becoming chronic in patients applying with acute ITP was 36.4%. Even though the number of acute cases was higher in the Infantile ITP group, there was no difference in terms of gender distribution.
Result:
It is possible to exclude history, examination, and laboratory as well as other causes of thrombocytopenia in patients applying with the ITP clinic. Morbidity and mortality due to ITP will have been prevented with the preference of effective and economic treatment methods. Prospectively planned comprehensive case studies are needed in order to determine the risk factors that might cause this disorder to reach a chronic state.

Keywords

Childhood, thrombocytopenia

References

• References 1. Diane J. Nugent immune thrombocytopenic purpura of childhood American Society of Hematology 2006; 97-102 2. Lilleyman JS. Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Arch Dis Child 1994; 71: 251-3 3. Blanchette, Bolton-Maggs. Chilhood Immune Thrombocytopenic Purpura: Diagnosis and Management, Pediatr Clin N Am 2008; 55:393-420 4. Lanzkowsky P. Disorders of Platelets. Manual of Pediatric Hematology and Oncology, Fourth Edition. Elsevier Inc, 2005;250-63. 5. Sutor AH, Harms A, Kaufmehl K. Acute immune thrombocytopenia in chilhood, retrospective and prospective survey in Germany. Semin thromb Hemost 2001; 27:253-7 6. Lileyman J S. Management of childhood idiopatic thrombocytopenic purpura. Br J Haematol 1999; 105:871-5 7. D.J Nugent Childdhood immune thrombocytopenic purpura Blood rewievs 2002; 16:27-9 8. Nathan DG, Oski FA Haematology of Infancy and Childhood, Acquired Platelet Defects. Sixth Edition. Saunders Company, Philadelphia, 2003;1597-1609 9. Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopenic purpura. Br J Clin Pharmacol 2003;55:107-11. 10. Scott J. Paul, Montgomery R.R. Hemorrhagic and thrombotic diseases In: Kliegman RM, Behrman RE, Jenson HB, Stanton, Nelson Essentials of Pediatrics 18th edition, Saunders Company 2007:2066-89 11. Kühne T, Imbach P, Buchanan GR, Zimmerman S. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr 2003;143:605-8. 12. Edslev PW, Rosthoj S, Treutiger I. A clinical score predicting a brief and uneventful course of newly diagnosed idiopathic thrombocytopenic purpura in children. Br J Haematol 2007;138:513-6. 13. Akbayram S, Dogan M, Ustyol L, Akgun C, Peker E, Bilici S et all. The Clinical Outcome of 260 Pediatric ITP Patients in One Center Clinical and Applied Thrombosis/Hemostasis 2011;17(6): E30-E35.